- Inhibitors
- Antibodies
- Compound Libraries
- New Products
- Contact Us
research use only
Cat.No.S9694
| Related Targets | CXCR Autophagy Nrf2 Mitophagy ULK FKBP Heme Oxygenase LC3 cGAS Cell wall |
|---|---|
| Other LRRK2 Products | LRRK2-IN-1 PFE-360 GNE-0877 (DNL201) GNE-7915 GSK2578215A Phospho-LRRK2 (Ser955) Antibody [F1M24] LRRK2 Antibody [P18P16] CZC-54252 GNE-9605 CZC-25146 |
| Cell Lines | Assay Type | Concentration | Incubation Time | Formulation | Activity Description | PMID |
|---|---|---|---|---|---|---|
| SH-SY5Y | Function assay | 90 mins | Inhibition LRRK2 G2019S mutant Ser935 phosphorylation in human SH-SY5Y cells after 90 mins by Western blot analysis, IC50 = 0.0048 μM. | 28245354 | ||
| Click to View More Cell Line Experimental Data | ||||||
|
In vitro |
DMSO
: 76 mg/mL
(200.28 mM)
Water : Insoluble Ethanol : Insoluble |
|
In vivo |
|||||
Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)
Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)
Calculation results:
Working concentration: mg/ml;
Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )
Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O, mix and clarify.
Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.
Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such
as vortex, ultrasound or hot water bath can be used to aid dissolving.
| Molecular Weight | 379.46 | Formula | C21H25N5O2 |
Storage (From the date of receipt) | 3 years -20°C powder |
|---|---|---|---|---|---|
| CAS No. | 1627091-47-7 | -- | Storage of Stock Solutions |
|
|
| Synonyms | N/A | Smiles | CC1CN(CC(C)O1)C2=CC(=NC=N2)C3=N[NH]C4=CC=C(OC5(C)CC5)C=C34 | ||
| Targets/IC50/Ki |
LRRK2
(purified LRRK2 kinase assay in vitro) 0.76 nM
LRRK2
(cellular assay monitoring dephosphorylation of LRRK2 pSer935 LRRK2) 1.4 nM
LRRK2
(radioligand competition binding assay) 3.4 nM
|
|---|---|
| In vitro |
MLi-2 is a structurally novel, highly potent, and selective LRRK2 kinase inhibitor with central nervous system activity. This compound exhibits exceptional potency in a purified LRRK2 kinase assay in vitro (IC50 = 0.76 nM), a cellular assay monitoring dephosphorylation of LRRK2 pSer935 LRRK2 (IC50 = 1.4 nM), and a radioligand competition binding assay (IC50 = 3.4 nM). It has greater than 295-fold selectivity for over 300 kinases in addition to a diverse panel of receptors and ion channels. |
| In vivo |
Acute oral and subchronic dosing in MLi-2 mice resulted in dosedependent central and peripheral target inhibition over a 24-hour period as measured by dephosphorylation of pSer935 LRRK2. Treatment of MitoPark mice with this compound is well tolerated over a 15-week period at brain and plasma exposures >100× the in vivo plasma IC50 for LRRK2 kinase inhibition as measured by pSer935 dephosphorylation. Morphologic changes in the lung, consistent with enlarged type II pneumocytes, are observed in this compound-treated MitoPark mice. |
References |
Tel: +1-832-582-8158 Ext:3
If you have any other enquiries, please leave a message.